These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 15011578)

  • 21. Switching from a toxicity-causing antiretroviral to enfuvirtide in patients with HIV: the SWITCH TOX study.
    Streinu-Cercel A; de Gorgolas M; Müller M; Portilla J; Rugina S; Böcher W; Staszewski S; Pulik P; Rowell L; Salgo M; Stoll M
    HIV Clin Trials; 2008; 9(6):375-86. PubMed ID: 19203903
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomized pilot study comparing combination therapy plus enfuvirtide versus a treatment interruption followed by combination therapy plus enfuvirtide.
    Beatty G; Hunt P; Smith A; Hoh R; Huang W; Martin J; Deeks SG
    Antivir Ther; 2006; 11(3):315-9. PubMed ID: 16759047
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fuzeon treatment forum, January 2004.
    Burgess GE
    Surviv News (Atlanta Ga); 2004; 15(1):10. PubMed ID: 15032144
    [No Abstract]   [Full Text] [Related]  

  • 24. Postmarketing use of enfuvirtide in veterans: provider compliance with criteria for use, overall efficacy, and tolerability.
    Belperio PS; Mole LA; Halloran J; Boothroyd DB; Thomas IC; Backus LI
    Ann Pharmacother; 2008 Nov; 42(11):1573-80. PubMed ID: 18940919
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enfuvirtide (T-20): a novel human immunodeficiency virus type 1 fusion inhibitor.
    Cervia JS; Smith MA
    Clin Infect Dis; 2003 Oct; 37(8):1102-6. PubMed ID: 14523775
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Enfuvirtide in HIV patients: a nursing guideline for medication management].
    Bigler S; Nicca D; Spirig R;
    Pflege; 2009 Feb; 22(1):29-38. PubMed ID: 19173176
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Short communication: evaluation of the effect of enfuvirtide in 11 HIV-1 vertically infected pediatric patients outside clinical trials.
    Palladino C; Briz V; González-Tomé MI; León Leal JA; Navarro ML; de José MI; Ramos JT; Muñoz-Fernández MA
    AIDS Res Hum Retroviruses; 2010 Mar; 26(3):301-5. PubMed ID: 20334565
    [TBL] [Abstract][Full Text] [Related]  

  • 28. TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretrovirals.
    Reynes J; Arastéh K; Clotet B; Cohen C; Cooper DA; Delfraissy JF; Eron JJ; Henry K; Katlama C; Kuritzkes DR; Lalezari JP; Lange J; Lazzarin A; Montaner JS; Nelson M; O' Hearn M; Stellbrink HJ; Trottier B; Walmsley SL; Buss NE; Demasi R; Chung J; Donatacci L; Guimaraes D; Rowell L; Valentine A; Wilkinson M; Salgo MP
    AIDS Patient Care STDS; 2007 Aug; 21(8):533-43. PubMed ID: 17711378
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enfuvirtide and cutaneous injection-site reactions.
    Mirza RA; Turiansky GW
    J Drugs Dermatol; 2012 Oct; 11(10):e35-8. PubMed ID: 23134996
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enfuvirtide: a novel agent for the treatment of HIV-1 infection.
    Duffalo ML; James CW
    Ann Pharmacother; 2003 Oct; 37(10):1448-56. PubMed ID: 14519027
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of switching from enfuvirtide to raltegravir in patients with virological suppression.
    Santos JR; Llibre JM; Ferrer E; Domingo P; Imaz A; Moltó J; Martin-Iguacel R; Caum C; Podzamczer D; Clotet B
    HIV Clin Trials; 2009; 10(6):432-8. PubMed ID: 20133273
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Selective increase in serum IgE following enfuvirtide administration in HIV-1 infected multidrug resistant patients.
    Hasson H; Biswas P; Galli L; Burastero SE; Danise A; Bigoloni A; Carini E; Locatelli M; Vecchi A; Lazzarin A; Castagna A
    New Microbiol; 2006 Oct; 29(4):223-30. PubMed ID: 17201088
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro characterization of a sustained-release formulation for enfuvirtide.
    Rothstein SN; Huber KD; Sluis-Cremer N; Little SR
    Antimicrob Agents Chemother; 2014; 58(3):1797-9. PubMed ID: 24366751
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of education and support on the tolerability and quality of life in a cohort of HIV-1 infected patients treated with enfuvirtide (SURCOUF Study).
    Allavena C; Prazuck T; Reliquet V; Verdon R; Perré P; Le Moal G; Billaud E; Raffi F
    J Int Assoc Physicians AIDS Care (Chic); 2008; 7(4):187-92. PubMed ID: 18599881
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Entry inhibitors: enfuvirtide, a reality for antiretroviral therapy].
    Pérez Plasencia A; Martínez Sánchez B
    Farm Hosp; 2004; 28(2):106-15. PubMed ID: 15101802
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enfuvirtide for nurses: answering patient questions on activity, safety, and lifestyle impact.
    Glutzer E; Lalezari JP
    J Assoc Nurses AIDS Care; 2005; 16(5):26-34. PubMed ID: 16433107
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HIV infection--a new drug and new costs.
    Steinbrook R
    N Engl J Med; 2003 May; 348(22):2171-2. PubMed ID: 12773643
    [No Abstract]   [Full Text] [Related]  

  • 38. Efficacy and safety of 48 weeks of enfuvirtide 180 mg once-daily dosing versus 90 mg twice-daily dosing in HIV-infected patients.
    Wright D; Rodriguez A; Godofsky E; Walmsley S; Labriola-Tompkins E; Donatacci L; Shikhman A; Tucker E; Chiu YY; Chung J; Rowell L; Demasi R; Graham N; Salgo M
    HIV Clin Trials; 2008; 9(2):73-82. PubMed ID: 18474492
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults.
    Kilby JM; Lalezari JP; Eron JJ; Carlson M; Cohen C; Arduino RC; Goodgame JC; Gallant JE; Volberding P; Murphy RL; Valentine F; Saag MS; Nelson EL; Sista PR; Dusek A
    AIDS Res Hum Retroviruses; 2002 Jul; 18(10):685-93. PubMed ID: 12167274
    [TBL] [Abstract][Full Text] [Related]  

  • 40. European Commission approves Fuzeon following FDA approval--first HIV-fusion inhibitor in fight against HIV.
    Infection; 2003 Aug; 31(4):7-8. PubMed ID: 14562955
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.